Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Constitution State Ledger.
Press releases published on April 4, 2025
University Archives' online-only auction, April 23rd, will feature over 60 lots dedicated to Abraham Lincoln
EIN Presswire
·
April 4, 2025
The Abraham Lincoln Collection represents over 60 lots ranging in estimate from $200 to $800,000, with over 12 items either written by or signed by Lincoln. WILTON, CT, UNITED STATES, April 4, 2025 /EINPresswire.com/ -- A vivid and lifelike photograph …
Grayscale Investments® Announces Rebalancing of Multi-Asset Funds for First Quarter 2025
GlobeNewswire
·
April 4, 2025
STAMFORD, Conn., April 04, 2025 (GLOBE NEWSWIRE) -- Grayscale Investments®, a leading crypto asset management firm, offering more than 30 crypto investment products, and manager of Grayscale® Digital Large Cap Fund (OTCQX: GDLC) (Digital Large Cap Fund), …
AC Reports Preliminary March 31 Book Value of $42.42 to $42.62 Per Share
GlobeNewswire
·
April 4, 2025
GREENWICH, Conn., April 04, 2025 (GLOBE NEWSWIRE) -- Associated Capital Group, Inc. (“AC” or the “Company”) (NYSE:AC), announced today a preliminary range for its first quarter book value of $42.42 to $42.62 per share. This compares to $42.14 per share at …
Leverage Shares by Themes Launches Three New Single Stock Leveraged ETFs, Bringing Investors Exciting Opportunities to Amplify Exposure to Square (XYZ), Salesforce (CRM), and PayPal (PYPL)
GlobeNewswire
·
April 4, 2025
GREENWICH, Conn., April 04, 2025 (GLOBE NEWSWIRE) -- Leverage Shares by Themes, an issuer of innovative exchange-traded products, is thrilled to announce the launch of three new single stock leveraged ETFs, available for trading starting April 4, 2025. …
Arvinas Presents First-in-Human Data for Investigational Oral PROTAC ARV-102 Demonstrating Blood-Brain Barrier Penetration, and Central and Peripheral LRRK2 Degradation
GlobeNewswire
·
April 4, 2025
– Data demonstrate that ARV-102 was well tolerated, orally bioavailable, and brain-penetrant; ARV-102 achieved central and peripheral LRRK2 reduction indicating substantial LRRK2 protein degradation in healthy volunteers – – Findings support continued …